BackVertex Pharmaceuticals Overview
Vertex Pharmaceuticals, Inc.

Vertex Pharmaceuticals Target Price

See Vertex Pharmaceuticals's analyst price targets ($560) vs the current share price.

Get informed when a big investor buys or sells

+ Follow

Share Price

$522.38

Average Target Price

$558.146.8% upside

14 analysts in the last 4 months

High: $665 | Low: $350

Analyst Recommendations

No recommendations in the last 4 months.

Revenue & Income Forecast

Analysts' Target Prices

DateAnalystPrice TargetCurrent Upside/Downside
2026-09-01Morgan StanleyTerence Flynn$66527.3% upsideOpen
2026-09-01Goldman Sachs$65325% upsideOpen
2026-08-11BernsteinJeffrey Walch$60816.4% upsideOpen
2026-08-10Wolfe ResearchAndy Chen$5627.6% upsideOpen
2026-08-05Truist Financial$5658.2% upsideOpen
2026-08-05Barclays$61718.1% upsideOpen
2026-08-04Stifel Nicolaus$5004.3% downsideOpen
2026-08-04Cantor Fitzgerald$59513.9% upsideOpen
2026-08-04Canaccord Genuity$44215.4% downsideOpen
2026-07-13UBS$58512% upsideOpen
2026-07-13Truist Financial$5607.2% upsideOpen
2026-07-07Robert W. Baird$35033% downsideOpen
2026-07-07RBC Capital$5709.1% upsideOpen
2026-05-27Truist FinancialDanielle Brill$5423.8% upsideOpen
2026-05-06Barclays$61517.7% upsideOpen
2026-05-05Morgan Stanley$61617.9% upsideOpen
2026-05-05RBC CapitalBrian Abrahams$5433.9% upsideOpen
2026-05-05Canaccord Genuity$43616.5% downsideOpen
2026-05-05Bernstein$5729.5% upsideOpen
2026-04-30Canaccord Genuity$43716.3% downsideOpen
2026-04-10Morgan Stanley$61217.2% upsideOpen
2026-03-10Truist FinancialJoon Lee$5250.5% upsideOpen
2026-03-10JefferiesAkash Tewari$58011% upsideOpen
2026-03-02BMO CapitalEvan David Seigerman$60014.9% upsideOpen
2026-02-17Canaccord Genuity$44115.6% downsideOpen
2026-02-17BarclaysEliana Merle$60716.2% upsideOpen
2026-02-17H.C. WainwrightAndrew Fein$59113.1% upsideOpen
2026-02-13Bernstein$57710.5% upsideOpen
2026-02-13RBC Capital$5413.6% upsideOpen
2026-02-13ScotiabankLouise Chen$5586.8% upsideOpen
2026-02-13Morgan StanleyTerence Flynn$5709.1% upsideOpen
2026-02-13Cantor Fitzgerald$59012.9% upsideOpen
2026-02-13H.C. WainwrightAndrew Fein$5180.8% downsideOpen
2026-02-13Stifel NicolausPaul Matteis$46610.8% downsideOpen
2026-01-27Barclays$60616% upsideOpen
2026-01-26UBS$5454.3% upsideOpen
2026-01-23Evercore ISICory Kasimov$5301.5% upsideOpen
2026-01-22RBC CapitalBrian Abrahams$5464.5% upsideOpen
2026-01-06UBSMichael Yee$5352.4% upsideOpen
2025-12-29Leerink Partners$5250.5% upsideOpen
2025-12-05Morgan Stanley$5648% upsideOpen
2025-12-03Morgan StanleyTerence Flynn$5161.2% downsideOpen
2025-11-04BarclaysGena Wang$41420.7% downsideOpen
2025-11-04Stifel Nicolaus$44514.8% downsideOpen
2025-11-04Cantor FitzgeraldCarter Gould$4857.2% downsideOpen
2025-11-04RBC Capital$41520.6% downsideOpen
2025-10-10Morgan Stanley$43816.2% downsideOpen
2025-09-25Leerink Partners$45612.7% downsideOpen
2025-08-05Stifel Nicolaus$45512.9% downsideOpen
2025-08-05Truist Financial$4906.2% downsideOpen

Vertex Pharmaceuticals (VRTX) FAQ

Vertex Pharmaceuticals posts a target price of $560. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

A target price of $560 for VRTX means covering analysts, on average, see the stock 6.8% upside of $522.38 over about 12 months. Dig into who set the high and low targets and how recently they updated — freshness matters as much as the average itself.

Context for VRTX's target price usually means three checks: (1) trend versus prior periods, (2) level versus peers, and (3) consistency with growth and profitability. This page covers the first two; Vertex Pharmaceuticals's other metric pages and overview cover the third.

Judging Vertex Pharmaceuticals against Healthcare peers is usually better than using a market-wide rule of thumb. Business models inside Healthcare are more comparable, which makes gaps in target price easier to interpret. Start with $560 here, then scan peer and history charts to see if the gap is persistent.